Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
:RAPP
RAPP Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RAPP Stock 12 Month Forecast
Average Price Target
$52.00
▲(95.56% Upside)
| Highest Price Target$77.00 | Average Price Target$52.00 | Lowest Price Target$34.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citizens JMP
$77
Buy
189.58%
Upside
Reiterated
09/23/25
Truist Financial
$44
Buy
65.48%
Upside
Initiated
09/16/25
Goldman Sachs
$51
Buy
91.80%
Upside
Assigned
09/12/25
Analysts Are Bullish on Top NA Stocks: Rubrik, Inc. Class A (RBRK), Rapport Therapeutics, Inc. (RAPP)Post the positive Ph2 proof-of-concept data for RAP-219 in focal onset epilepsy (FOS), we assign a Buy rating to RAPP with a $51, 12-month price target, from the previous Early-Stage Biotech (ESB) designation.
H.C. Wainwright
$31→$34
Buy
27.87%
Upside
Reiterated
09/08/25
TD Cowen
―
Buy
―
Reiterated
09/08/25
JonesTrading
$42→$50
Buy
88.04%
Upside
Reiterated
09/08/25
Jefferies
$35
Buy
31.63%
Upside
Assigned
12/07/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citizens JMP
$77
Buy
189.58%
Upside
Reiterated
09/23/25
Truist Financial
$44
Buy
65.48%
Upside
Initiated
09/16/25
Goldman Sachs
$51
Buy
91.80%
Upside
Assigned
09/12/25
Analysts Are Bullish on Top NA Stocks: Rubrik, Inc. Class A (RBRK), Rapport Therapeutics, Inc. (RAPP)Post the positive Ph2 proof-of-concept data for RAP-219 in focal onset epilepsy (FOS), we assign a Buy rating to RAPP with a $51, 12-month price target, from the previous Early-Stage Biotech (ESB) designation.
H.C. Wainwright
$31→$34
Buy
27.87%
Upside
Reiterated
09/08/25
TD Cowen
―
Buy
―
Reiterated
09/08/25
JonesTrading
$42→$50
Buy
88.04%
Upside
Reiterated
09/08/25
Jefferies
$35
Buy
31.63%
Upside
Assigned
12/07/24
Best Analysts Covering Rapport Therapeutics, Inc.
1 Month
xxx
Success Rate
4/9 ratings generated profit
Average Return
-1.97%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 44.44% of your transactions generating a profit, with an average return of -1.97% per trade.
3 Months
xxx
Success Rate
5/9 ratings generated profit
Average Return
+9.54%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +9.54% per trade.
1 Year
Success Rate
7/9 ratings generated profit
Average Return
+81.56%
reiterated a buy rating 20 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +81.56% per trade.
2 Years
xxx
Success Rate
6/7 ratings generated profit
Average Return
+54.21%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +54.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RAPP Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
5
7
6
11
14
Buy
2
3
3
3
3
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
10
9
14
17
Each month's total comprises the sum of three months' worth of ratings.
RAPP Financial Forecast
RAPP Stock Forecast FAQ
What is RAPP’s average 12-month price target, according to analysts?
Based on analyst ratings, Rapport Therapeutics, Inc.’s 12-month average price target is 52.00.
What is RAPP’s upside potential, based on the analysts’ average price target?
Rapport Therapeutics, Inc. has 95.56% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RAPP a Buy, Sell or Hold?
Rapport Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Rapport Therapeutics, Inc.’s price target?
The average price target for Rapport Therapeutics, Inc. is 52.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $77.00 ,the lowest forecast is $34.00. The average price target represents 95.56% Increase from the current price of $26.59.
The highest analyst price target is $77.00 ,the lowest forecast is $34.00. The average price target represents 95.56% Increase from the current price of $26.59.
What do analysts say about Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of RAPP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.